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INTRODUCTION:  Rhabdomyolysis  associated  with  the  use  of  pregabalin  or azithromycin  has  been  demon-
strated  to be a rare  but potentially  life-threatening  adverse  event.  Here,  we  report  an  extremely  rare  case
of rhabdomyolysis  with  purpura  in  a patient  who  had  used  pregabalin  and  azithromycin.
PRESENTATION  OF  CASE:  We  present  the case  of a 75-year-old  woman  with  a history  of  ﬁbromyalgia  who
was  admitted  with  mild  limb  weakness  and  lower  abdominal  purpura.  She  was  prescribed  pregabalin
(75  mg,  twice  daily)  for almost  3 months  to treat  chronic  back pain.  Her medical  history  revealed  that
3  days  before  admission,  she  began  experiencing  acute  bronchitis  and  was  treated  with  a  single  dose  of
azithromycin  (500  mg).  She  had  developed  rapid  onset  severe  myalgia,  mild  whole  body  edema,  muscle
weakness  leading  to  gait  instability,  abdominal  purpura  and  tender  purpura  on the  lower  extremities.
Laboratory  values  included  a white  blood  cell  count  of 25,400/mL  and a creatinine  phosphokinase  (CPK)
concentration  of  1250  IU/L. Based  on  these  ﬁndings  and  the patient’s  clinical  history, a  diagnosis  of
pregabalin-  and  azithromycin-induced  rhabdomyolysis  was  made.
DISCUSSION:  The  long-term  use  of pregabalin  and  the initiation  azithromycin  therapy  followed  by a  rapid
onset  of  rhabdomyolysis  is indicative  of  a drug  interaction  between  pregabalin  and  azithromycin.
CONCLUSION:  We  report an  extremely  rare case  of  rhabdomyolysis  with  purpura  caused  by a  drug  inter-
action  between  pregabalin  and azithromycin.  However,  the  mechanisms  of the  interactions  between
azithromycin  on  the  pregabalin  are still  unknown.
©  2016  The  Author(s).  Published  by  Elsevier  Ltd  on behalf  of IJS  Publishing  Group  Ltd.  This  is  an  open
he  CCaccess  article  under  t
. Introduction
The typical clinical presentation of rhabdomyolysis includes
uscle weakness, myalgia and dark-colored urine due to myo-
lobinuria. The diagnosis is usually based on elevated serum
keletal muscle enzyme levels [1]. Pregabalin is a ligand that
cts as a -aminobutyric acid (GABA) analogue and binds to the
lpha-2- subunit of the voltage-gated calcium channels in the
entral nervous system. The FDA has approved its use for the
reatment of postherpetic neuralgia (PHN), ﬁbromyalgia, diabetic
eripheral neuropathic pain, and several neuropathic pain [2].
zithromycin interferes weakly with cytochrome P450 (CYP) 3A4
nd has been reported to cause rhabdomyolysis through interac-
∗ Corresponding author.
E-mail address: pippuclinickato@gold.ocn.ne.jp (K. Kato).
ttp://dx.doi.org/10.1016/j.ijscr.2016.07.007
210-2612/© 2016 The Author(s). Published by Elsevier Ltd on behalf of IJS Publishing 
reativecommons.org/licenses/by-nc-nd/4.0/). BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
tions with several statins [3]. Pregabalin is not recognized as a
cause of rhabdomyolysis. Rhabdomyolysis associated with the use
of pregabalin has been demonstrated to be rare but potentially
life-threatening [4]. Cutaneous eruptions and purpura in cases of
rhabdomyolysis are infrequent. Here, we report an extremely rare
case of rhabdomyolysis with purpura in a patient who had used
pregabalin and azithromycin. To our knowledge, this case is the
ﬁrst report of pregabalin- and azithromycin-induced rhabdomyol-
ysis with purpura. We  report this rare case and review the related
literature.
2. Presentation of caseThe patient was a 75-year-old woman with chronic back pain
who also had hyperlipidemia. Her past medical history included
the use of fenoﬁbrate (100 mg,  once daily) to treat hypertriglyc-
eridemia (serum triglyceride level: 366 mg/dl) for almost 3 months.
Group Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Fig. 1. Bilateral purpura on the lower abdomen in a straight line with slight edema.
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wig. 2. a, b: Purpura on the lower extremities and ecchymotic lesions on the back.
enoﬁbrate was discontinued once her triglyceride level returned
o normal. Two months later, she was started on pregabalin (75 mg,
wice daily) for chronic lower back pain. This occurred 3 months
efore presentation with rhabdomyolysis. Her past medical his-
ory included the following pertinent factors: no recent viral illness,
istory of trauma, or epilepsy, and the absence of any other med-
cations that could potentially be associated with rhabdomyolysis.
he patient’s medical history revealed that 3 days before admission,
he began experiencing acute bronchitis and was treated with a sin-
le dose of azithromycin (500 mg). She had developed rapid-onset
evere myalgia and muscle weakness over these 3 days, which led
o gait instability. Physical examination revealed well-demarcated
ilateral purpura on the lower abdomen in a straight line with
 small lesion in the right anterior femoral area (Figs. 1 and 2a).
zithromycin use was then discontinued.
Upon admission, the patient had slight, generalized muscle pain
nd weakness and the following laboratory values: white blood
ell count, 24,000/l; platelet count, 294,000/l; aspartate amino-
ransferase (AST), 38 U/L; alanine aminotransferase (ALT), 31 U/L;
actate dehydrogenase (LDH), 329 U/L; triglycerides, 138 mg/dl;
otal cholesterol, 187 mg/dl; creatine, 0.7 mg/dl; creatinine phos-
hokinase (CPK), 1250 U/L (reference range: 40–170 U/L); blood
rea nitrogen (BUN), 26 mg/dl (reference range: 8–15 mg/dl); pro-
hrombin time, 11.3 s; active partial prothrombin time, 31.4 s;
brinogen degradation product, 41.6 g/mL; and D-dimer, 22.9
ic/mL (reference range: 0–1.0 mic/mL). The elevated CPK was  not
ardiac in origin because both electrocardiography and myocardial
nzyme markers were within normal limits. Urinalysis was consis-
ent with myoglobinuria. One day after admission, she had tender
rythematous lesions on her back (Fig. 2b). A computed tomogra-
hy (CT) scan of her head was negative for a hemorrhage and an
nfarction. Based on these ﬁndings and the clinical history, a diagno-
is of pregabalin- and azithromycin-induced rhabdomyolysis with
ower abdominal purpura was made [5]. Pregabalin was then dis-
ontinued. Five days later, the patient had signiﬁcantly improved
nd CPK levels began to decline. All conditions, including purpura,
eturned to normal within three weeks.. Discussion
Rhabdomyolysis can be caused by various drugs and toxins, as
ell as by mechanical, viral and metabolic factors. Several fac-PEN  ACCESS
ery Case Reports 26 (2016) 221–223
tors have been identiﬁed that increase the risk for both myopathy
and rhabdomyolysis, including advanced age, chronic renal fail-
ure (CRF), metabolic disorders, major surgery, and alcohol abuse
[6,7]. The clinical manifestations of rhabdomyolysis are nonspe-
ciﬁc. This condition presents as myalgia, weakness, fatigue, and
dark-colored urine, which usually develop within a few days of
starting the treatment. The most noteworthy adverse reactions
associated with statins are elevations in symptoms associated with
myopathy and rhabdomyolysis, which is characterized by mas-
sive muscle necrosis, myoglobinuria, and acute renal failure [8].
Pravastatin monotherapy is associated with the potentially fatal
occurrence of rhabdomyolysis, which induces DIC and purpura
fulminans [9]. In a recently published review, it was  suggested
that myopathy occurred in 20% of patients receiving statin ther-
apy [10]. The risk of rhabdomyolysis with statin monotherapy is
dose-dependent. The adverse events associated with pravastatin,
simvastatin, atorvastatin, and rosuvastatin submitted to the FDA
include myalgia, rhabdomyolysis, an increase in CPK levels and
other muscular events.
Pregabalin is not recognized as a cause of rhabdomyolysis. A
previous report showed a 0.8% incidence of CPK elevation in a pre-
gabalin group compared with a 0.4% incidence in a control group
[11]. There are three case reports and three premarketing reports of
rhabdomyolysis associated with pregabalin [1,2,12,13]. The mech-
anism by which rhabdomyolysis occurs with pregabalin is poorly
deﬁned. The occurrence is known to increase with dosage [14].
Sakamoto [15] found that ﬂuvastatin and pravastatin induced the
formation of numerous vacuoles in the myoﬁbers of rats after
72 h of treatment and the inactivation of Rab GPTase, which is
involved in intracellular membrane transport and is a crucial factor
in statin-induced-morphological abnormalities in skeletal mus-
cle ﬁbers. This risk increase in patients taking concomitant drugs
that inhibit cytochrome P450 (mainly CYP2C9 or CYP3A4)-related
statin metabolism, such as azole antifungals, cyclosporine, ﬁbrates,
macrolides, and non-dihydropyridine calcium-channel blockers
[16].
Pregabalin does not inhibit hepatic metabolism or cytochrome
P450 metabolism. Pregabalin is rapidly absorbed after oral admin-
istration, with 90% oral bioavailability. The plasma concentration
is obtained in 24–48 h. It does not bind plasma proteins, has an
elimination half-life of approximately 6 h, and 98% is excreted
unchanged in urine [17]. Common adverse reactions include cen-
tral nervous system depression and dizziness. Various infectious
agents may  cause rhabdomyolysis [18], and consequently, the
infection for which azithromycin was  given could have led to
rhabdomyolysis without any drug interaction. Rhabdomyolysis
associated with azithromycin monotherapy is extremely rare and
may  result in myoglobinuria. Clarithromycin and erythromycin, but
not azithromycin, inhibit CYP3A4.
Recently, several case reports have suggested that the
interaction between azithromycin and statins may  result in rhab-
domyolysis [3]. Azithromycin has been reported to increase the
bioavailability of ivermectin, a substrate or the transporter of P-
glycoprotein and CYP3A4 [3,19]. This evidence is suggestive of a
drug interaction between statins and azithromycin. The long-term
use of pregabalin associated with a rapid onset, within few days,
of rhabdomyolysis after azithromycin use is indicative of a drug
interaction in our case. It is not known whether the combination
of pregabalin and azithromycin increases the risk of myositis or
rhabdomyolysis. No known interactions have been published to
date between pregabalin and azithromycin. Cutaneous eruption or
purpura is extremely rare in patients with rhabdomyolysis. Some
authors have reported that well demarcated erythema, violaceous
plaques and petechiae, and ulcers occur several hours or days after
the application of pressure to a speciﬁc area. Tissue hypoxia and
pressure are considered to be causative factors for skin eruption
 –  O
f Surg
o
p
a
k
b
4
e
e
p
p
p
C
F
E
b
C
p
C
i
b
A
r
a
c
[
[
[
[
[
[
[
[
[
O
T
p
cCASE  REPORT
K. Kato et al. / International Journal o
r purpura [5,20]. Bilateral linear purpura might be caused by the
ressure from underwear in our case.
This case report suggests an interaction between pregabalin
nd azithromycin resulting in rhabdomyolysis. To the best of our
nowledge, this is the ﬁrst report of a combined therapy with prega-
alin and azithromycin resulting in rhabdomyolysis with purpura.
. Conclusions
In summary, pregabalin was associated with a potentially fatal
vent of rhabdomyolysis in a patient using azithromycin. How-
ver, the details of the interaction between azithromycin and the
regabalin are still unknown. We  report an extremely rare case of
regabalin- and azithromycin-induced rhabdomyolysis with pur-
ura.
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Key learning points
• Pregabalin and azithromycin therapy is associated with a poten-
tially fatal occurrence of rhabdomyolysis with purpura.
• The mechanisms of the interactions between azithromycin on the
pregabalin are still unknown.
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